Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Cash from Operations for 7 consecutive years, with -$44.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 9.98% year-over-year to -$44.3 million; the trailing twelve-month figure through Jun 2026 stood at -$170.2 million (up 28.38% YoY), and the FY2025 full-year result was -$171.1 million, up 46.47% from the prior year.
• Cash from Operations advanced to -$44.3 million in Q2 2026 per DNA's latest filing, from -$46.7 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$19.9 million in Q1 2022 and bottomed at -$104.5 million in Q4 2022.
• Historically, Cash from Operations has averaged -$62.7 million across 5 years, with a median of -$54.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 441.76% in 2022, then soared 69.46% in 2025.
• Over 5 years, Cash from Operations stood at -$104.5 million in 2022, then surged by 44.68% to -$57.8 million in 2023, then climbed by 26.62% to -$42.4 million in 2024, then declined by 12.36% to -$47.7 million in 2025, then increased by 7.14% to -$44.3 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$44.3 million, -$46.7 million, and -$47.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.